Key facts
- This page summarizes Theodore R. Schroeder's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Apr 2025, 17:44.
Theodore R. Schroeder - 16 Apr 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- Director
- Issuer ticker
- PHAT
- Reported as of
- 16 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Apr 2025, 17:44:03 UTC
- Prior SEC filing
- 19 Dec 2024
- Next SEC filing
- 18 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Molly Henderson, Attorney-in-Fact for Theodore R. Schroeder
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Theodore R. Schroeder filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 16 Apr 2025.
Change
- Previous filing in this sequence was filed on 19 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHAT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +21,000
- Change %
- Price
- $0.000000
- Shares after
- 21,000
- Date
- 16 Apr 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHAT
transaction
Derivative
Common Stock (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 16 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $4.23
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted on April 16, 2025. One-third (1/3) of the total number of RSUs granted vest on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Footnote F2
The stock option will vest with respect to one-third (1/3) of the shares of common stock on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.